Antihypertensive medication use and incident breast cancer in women

Breast Cancer Research and Treatment

Volumn 150, Issue 1, 2015, Pages 219-229

  Devore, Elizabeth E ^a,g   Kim, Sung ^b   Ramin, Cody A ^a,c   Wegrzyn, Lani R ^d   Massa, Jennifer ^d   Holmes, Michelle D ^a,d   Michels, Karin B ^a,d,e   Tamimi, Rulla M ^a,d   Forman, John P ^a   Schernhammer, Eva S ^a,d,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^g Brigham and Women’s Hospital ^*  (United States)

Author keywords

Antihypertensive medication; Breast cancer; Cohort study; Epidemiology

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; NURSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK ASSESSMENT; TREATMENT DURATION; BREAST NEOPLASMS; HEALTH SURVEY; INCIDENCE; MIDDLE AGED; ODDS RATIO; REGISTER; RISK FACTOR; UNITED STATES;

ADULT; ANTIHYPERTENSIVE AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NURSES; ODDS RATIO; POPULATION SURVEILLANCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84925538342     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3311-9     Document Type: Article

References (32)

1. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P (2011) Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 57(6):1101–1107. doi:10.1161/HYPERTENSIONAHA.110.168005
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572. doi:10.1001/jama.289.19.2560
3. Group USCSW (2013) United States Cancer Statistics: 1999-2010 Incidence and mortality web-based report. Atlanta, GA
4. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB, Havlik RJ (1996) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348(9026):493–497. doi:10.1016/S0140-6736(96)04277-8
5. Jick H, Jick SS, Myers MW, Vasilakis C (1997) Third-generation oral contraceptives and venous thrombosis. Lancet 349(9053):731–732; author reply 732–733. doi:10.1016/S0140-6736(05)60173-0
6. Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, Andersen M, Fraumeni JF Jr, Olsen J (1997) Cancer risk in users of calcium channel blockers. Hypertension 29(5):1091–1094
7. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shapiro S (1998) Calcium channel blockers and the risk of cancer. JAMA 279(13):1000–1004
8. Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE, Colditz GA, Hennekens CH, Willett WC (1998) Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses’ health study. Cancer 83(9):2003–2007
9. Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK, Baron JA (2000) Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer 89(1):165–170
10. Meier CR, Derby LE, Jick SS, Jick H (2000) Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 160(3):349–353
11. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH (2001) Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92(9):2462–2470
12. Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA (2004) Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 13(8):581–585. doi:10.1002/pds.910
13. Fryzek JP, Ye W, Nyren O, Tarone RE, Lipworth L, McLaughlin JK (2006) A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women. Breast Cancer Res Treat 97(2):131–134. doi:10.1007/s10549-005-9099-2
14. Coogan PF, Strom BL, Rosenberg L (2009) Diuretic use and the risk of breast cancer. J Hum Hypertens 23(3):216–218. doi:10.1038/jhh.2008.131
15. Bergman GJ, Khan S, Danielsson B, Borg N (2014) Breast cancer risk and use of calcium channel blockers using Swedish population registries. JAMA Intern Med. doi:10.1001/jamainternmed.2014.3867
16. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (1997) Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 80(8):1438–1447
17. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352(9123):179–184. doi:10.1016/S0140-6736(98)03228-0
18. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer 98(7):1504–1513. doi:10.1002/cncr.11663
19. Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J, Leighton N, Peel D, Anton-Culver H (2006) Hypertension, diuretics and breast cancer risk. J Hum Hypertens 20(10):727–732. doi:10.1038/sj.jhh.1002075
20. Largent JA, Bernstein L, Horn-Ross PL, Marshall SF, Neuhausen S, Reynolds P, Ursin G, Zell JA, Ziogas A, Anton-Culver H (2010) Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort. Cancer Causes Control 21(10):1615–1624. doi:10.1007/s10552-010-9590-x
21. Saltzman BS, Weiss NS, Sieh W, Fitzpatrick AL, McTiernan A, Daling JR, Li CI (2013) Use of antihypertensive medications and breast cancer risk. Cancer Causes Control 24(2):365–371. doi:10.1007/s10552-012-0122-8
22. Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE (2013) Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 173(17):1629–1637. doi:10.1001/jamainternmed.2013.9071
23. Colditz GA (1995) The nurses’ health study: a cohort of US women followed since 1976. J Am Med Women’s Assoc 50(2):40–44
24. Rich-Edwards JW, Goldman MB, Willett WC, Hunter DJ, Stampfer MJ, Colditz GA, Manson JE (1994) Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol 171(1):171–177
25. Wang J, Eliassen AH, Spiegelman D, Willett WC, Hankinson SE (2014) Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses’ Health Study II. Cancer Causes Control. doi:10.1007/s10552-014-0383-5
26. Fung TT, Chiuve SE, Willett WC, Hankinson SE, Hu FB, Holmes MD (2013) Intake of specific fruits and vegetables in relation to risk of estrogen receptor-negative breast cancer among postmenopausal women. Breast Cancer Res Treat 138(3):925–930. doi:10.1007/s10549-013-2484-3
27. Baer HJ, Rich-Edwards JW, Colditz GA, Hunter DJ, Willett WC, Michels KB (2006) Adult height, age at attained height, and incidence of breast cancer in premenopausal women. Int J Cancer 119(9):2231–2235. doi:10.1002/ijc.22096
28. Holmes MD, Hankinson SE, Feskanich D, Chen WY (2013) Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 139(2):507–513. doi:10.1007/s10549-013-2553-7
29. Stoschitzky K, Sakotnik A, Lercher P, Zweiker R, Maier R, Liebmann P, Lindner W (1999) Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 55(2):111–115
30. Schernhammer ES, Hankinson SE (2005) Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 97(14):1084–1087. doi:10.1093/jnci/dji190
31. Schernhammer ES, Hankinson SE (2009) Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomark Prev 18(1):74–79. doi:10.1158/1055-9965.EPI-08-0637
32. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE (1986) Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 123(5):894–900